SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the

Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free

Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Easte

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) rose 3.7% during trading on Monday after

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report)'s share price was up 3.7% during trading

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem bought 5,000 shares o

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) Director Jon Kayyem purchased 5,000 share

The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82

Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory

Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology ma

Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase

Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106

Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in

First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizuma

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRN

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.

HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:IN

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 a

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nas

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investo

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Oz

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, O

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "

U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares

US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrad

Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading streng

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company anno

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Friday, 422 stocks made new 52-week lows.

  During the Thursday's session, 100 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

Following the market opening Tuesday, the Dow traded down 1.79% to 33,748.82 while the NASDAQ fell 2

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched

Gainers

Gainers